Tamsulosin Associated with Interstitial Lung Damage in CYP2D6 Variant Alleles Carriers
Abstract
:1. Introduction
2. Results
2.1. Description of the Cases
2.2. Genotyping
3. Discussion
4. Methods
4.1. Patients and Methods
4.2. Genotyping
4.3. Statistical Analysis
5. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Ahmed, S.; Zhou, Z.; Zhou, J.; Chen, S.Q. Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine. Genom. Proteom. Bioinform. 2016, 14, 298–313. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mitchell, J.R.; Jollow, D.J.; Potter, W.Z.; Gillette, J.R.; Brodie, B.B. Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. J. Pharm. Exp. 1973, 187, 211–217. [Google Scholar]
- Hukkanen, J.; Pelkonen, O.; Raunio, H. Expression of xenobiotic-metabolizing enzymes in human pulmonary tissue: Possible role in susceptibility for ILD. Eur. Respir. J. Suppl. 2001, 32, 122s–126s. [Google Scholar] [PubMed]
- Skeoch, S.; Weatherley, N.; Swift, A.J.; Oldroyd, A.; Johns, C.; Hayton, C.; Giollo, A.; Wild, J.M.; Waterton, J.C.; Buch, M.; et al. Drug-Induced Interstitial Lung Disease: A Systematic Review. J. Clin. Med. 2018, 7, 356. [Google Scholar] [CrossRef] [Green Version]
- Camus, P.; Bonniaud, P.; Fanton, A.; Camus, C.; Baudaun, N.; Foucher, P. Drug-induced and iatrogenic infiltrative lung disease. Clin. Chest. Med. 2004, 25, 479–519. [Google Scholar] [CrossRef]
- Pneumotox. The Drug-Induced Respiratory Diasease Website. Available online: www.pneumotox.com (accessed on 3 December 2019).
- Wijnen, P.A.; Drent, M.; Nelemans, P.J.; Kuijpers, P.M.; Koek, G.H.; Neef, C.; Haenen, G.R.; Bekers, O. Role of cytochrome P450 polymorphisms in the development of pulmonary drug toxicity: A case-control study in the Netherlands. Drug Saf. 2008, 31, 1125–1134. [Google Scholar] [CrossRef]
- Kamimura, H.; Oishi, S.; Matsushima, H.; Watanabe, T.; Higuchi, S.; Hall, M.; Wood, S.G.; Chasseaud, L.F. Identification of cytochrome P450 isozymes involved in metabolism of the alpha1-adrenoceptor blocker tamsulosin in human liver microsomes. Xenobiotica 1998, 28, 909–922. [Google Scholar] [CrossRef]
- Muller, B.; Zopf, K.; Bachofer, J.; Steimer, W. Optimized strategy for rapid cytochrome P450 2D6 genotyping by real-time long PCR. Clin. Chem. 2003, 49, 1624–1631. [Google Scholar] [CrossRef] [Green Version]
- Matsuno, O. Drug-induced interstitial lung disease: Mechanisms and best diagnostic approaches. Respir. Res. 2012, 13. [Google Scholar] [CrossRef] [Green Version]
- Jessurun, N.T.; Drent, M.; van Puijenbroek, E.P.; Bekers, O.; Wijnen, P.A.; Bast, A. Drug-induced interstitial lung disease: Role of pharmacogenetics in predicting cytotoxic mechanisms and risks of side effects. Curr. Opin. Pulm. Med. 2019, 25, 468–477. [Google Scholar] [CrossRef]
- Williams, D.P.; Park, B.K. Idiosyncratic toxicity: The role of toxicophores and bioactivation. Drug Discov. Today 2003, 8, 1044–1050. [Google Scholar] [CrossRef]
- Kalgutkar, A.S.; Gardner, I.; Obach, R.S.; Shaffer, C.L.; Callegari, E.; Henne, K.R.; Mutlib, A.E.; Dalvie, D.K.; Lee, J.S.; Nakai, Y.; et al. A comprehensive listing of bioactivation pathways of organic functional groups. Curr. Drug Metab. 2005, 6, 161–225. [Google Scholar] [CrossRef] [PubMed]
- Stepan, A.F.; Walker, D.P.; Bauman, J.; Price, D.A.; Baillie, T.A.; Kalgutkar, A.S.; Aleo, M.D. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: A perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. Chem. Res. Toxicol. 2011, 24, 1345–1410. [Google Scholar] [CrossRef]
- Regan, S.L.; Maggs, J.L.; Hammond, T.G.; Lambert, C.; Williams, D.P.; Park, B.K. Acyl glucuronides: The good, the bad and the ugly. Biopharm. Drug Dispos. 2010, 31, 367–395. [Google Scholar] [CrossRef] [PubMed]
- Travis, W.D.; Costabel, U.; Hansell, D.M.; King, T.E., Jr.; Lynch, D.A.; Nicholson, A.G.; Ryerson, C.J.; Ryu, J.H.; Selman, M.; Wells, A.U.; et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 2013, 188, 733–748. [Google Scholar] [CrossRef]
- Wuyts, W.A.; Cavazza, A.; Rossi, G.; Bonella, F.; Sverzellati, N.; Spagnolo, P. Differential diagnosis of usual interstitial pneumonia: When is it truly idiopathic? Eur. Respir. Rev. 2014, 23, 308–319. [Google Scholar] [CrossRef] [Green Version]
- Théophile, H.; André, M.; Miremont-Salamé, G.; Arimone, Y.; Bégaud, B. Comparison of Three Methods (An Updated Logistic Probabilistic Method, the Naranjo and Liverpool Algorithms) for the Evaluation of Routine Pharmacovigilance Case Reports Using Consensual Expert Judgement as Reference. Drug Saf. 2013, 36, 1033–1044. [Google Scholar] [CrossRef]
- Kane-Gill, S.L.; Kirisci, L.; Pathak, D.S. Are the Naranjo criteria reliable and valid for determination of adverse drug reactions in the intensive care unit? Ann. Pharm. 2005, 39, 1823–1827. [Google Scholar] [CrossRef]
- Jessurun, N.; van Puijenbroek, E.P.; Otten, L.S.; Mikes, O.; Vermeulen, W.A.; van Marum, R.J.; Grootens, K.; Derijks, H.J. Inhibition of CYP2D6 with low dose (5 mg) paroxetine in patients with high 10-hydroxynortriptyline serum levels—A review of routine practice. Br. J. Clin. Pharm. 2017, 83, 1149–1151. [Google Scholar] [CrossRef] [Green Version]
- Drent, M.; Singh, S.; Gorgels, A.P.; Hansell, D.M.; Bekers, O.; Nicholson, A.G.; van Suylen, R.J.; du Bois, R.M. Drug-induced pneumonitis and heart failure simultaneously associated with venlafaxine. Am. J. Respir. Crit. Care Med. 2003, 167, 958–961. [Google Scholar] [CrossRef] [Green Version]
- Drent, M.; Wijnen, P.; Bast, A. Interstitial lung damage due to cocaine abuse: Pathogenesis, pharmacogenomics and therapy. Curr. Med. Chem. 2012, 19, 5607–5611. [Google Scholar] [CrossRef] [PubMed]
- Wijnen, P.A.; Limantoro, I.; Drent, M.; Bekers, O.; Kuijpers, P.M.; Koek, G.H. Depressive effect of an antidepressant: Therapeutic failure of venlafaxine in a case lacking CYP2D6 activity. Ann. Clin. Biochem. 2009, 46, 527–530. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wijnen, P.A.; Bekers, O.; Drent, M. Development of cocaine-induced interstitial lung damage in two CYP2C and VKORC1 variant allele carriers. Mol. Diagn. 2011, 15, 177–180. [Google Scholar] [CrossRef] [PubMed]
- Drent, M.; Wijnen, P.; Bast, A. Pharmacogenetic variants and vitamin K deficiency: A risk factor or trigger for fibrosing interstitial pneumonias? Curr. Opin. Pulm. Med. 2018, 24, 287–295. [Google Scholar] [CrossRef]
- Bodelier, A.G.; Masclee, A.A.; Bakker, J.A.; Hameeteman, W.H.; Pierik, M.J. Azathioprine induced pneumonitis in a patient with ulcerative colitis. J. Crohns Colitis 2009, 3, 309–312. [Google Scholar] [CrossRef]
- Naranjo, C.A.; Busto, U.; Sellers, E.M.; Sandor, P.; Ruiz, I.; Roberts, E.A.; Janecek, E.; Domecq, C.; Greenblatt, D.J. A method for estimating the probability of adverse drug reactions. Clin. Pharm. 1981, 30, 239–245. [Google Scholar] [CrossRef]
- R Core Team. R: A Language and Environment for Statistical Computing; R Foundation for Statistical Computing: Vienna, Austria, 2018. [Google Scholar]
Patient | Age (Years) | Diagnosis, Condition after Withdrawal of Tamsulosin | Genotype | Concomitant Drugs and the Most Important Metabolizing Cytochrome P450 Isoenzyme for Them | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
CYP2D6 (including Phenotype) | CYP2C9 | CYP3A4 | CYP3A5 | CYP2C19 | CYP2D6 | CYP2C9 | CYP2C19 | |||||
1 | 70 | NSIP, stabilized | *4/*41 | AS: 0.5 | (IM) | *1/*2 | *1A/*1A | *3/*3 | *1/*1 | |||
2 | 84 | NSIP, stabilized | *4/*4 | AS: 0.0 | (PM) | *1/*2 | *1A/*1A | *3/*3 | *1/*1 | Metoprolol | Valsartan | |
3 | 79 | NSIP, stabilized | *4/*6 | AS: 0.0 | (PM) | *2/*3 | *1A/*1A | *3/*3 | *1/*1 | |||
4 | 93 | IPF, stabilized | *4/*4 | AS: 0.0 | (PM) | *1/*1 | *1A/*1A | *3/*3 | *1/*2 | Metoprolol | ||
5 | 87 | IPF, stabilized | *3/*4 | AS: 0.0 | (PM) | *1/*1 | *1A/*1B | *1/*3 | *1/*1 | |||
6 | 79 | IPF, stabilized | *4/*4 | AS: 0.0 | (PM) | *1/*2 | n/a | n/a | *1/*1 | Metoprolol | ||
7 | 76 | IPF, stabilized # | *1/*4 | AS: 1.0 | (IM) | *1/*2 | *1A/*1A | *3/*3 | *1/*2 | |||
8 | 83 | NSIP, improved | *1/*4 | AS: 1.0 | (IM) | *1/*1 | n/a | n/a | *1/*1 | |||
9 | 72 | NSIP, improved | *1/*4 | AS: 1.0 | (IM) | *1/*2 | *1A/*1A | *3/*3 | *1/*1 | |||
10 | 77 | NSIP, improved | *1/*4 | AS: 1.0 | (IM) | *1/*1 | n/a | *1/*3 | *1/*1 | Metoprolol | ||
11 | 71 | IPF, died from pneumonia | *4/*4 | AS: 0.0 | (PM) | *1/*1 | *1A/*1A | *3/*3 | *1/*2 | |||
12 | 79 | IPF, died from cardiac failure | *5/*5 | AS: 0.0 | (PM) | *1/*2 | *1A/*1A | *3/*3 | *1/*1 | Losartan | Clopidogrel | |
13 | 79 | IPF, died from respiratory failure | *1/*4 | AS: 1.0 | (IM) | *1/*1 | *1A/*1A | *3/*3 | *2/*2 | |||
14 | 68 | IPF, died from respiratory failure | *1/*4 | AS: 1.0 | (IM) | *1/*1 | *1A/*1A | *3/*3 | *2/*2 | |||
15 | 74 | IPF, died from respiratory failure | *4/*6 | AS: 0.0 | (PM) | *1/*2 | *1A/*1A | *3/*3 | *1/*1 | Metoprolol | Rosuvastatin | |
16 | 80 | NSIP, died from cardiac failure | *1/*3 | AS: 1.0 | (IM) | *1/*1 | *1A/*1B | *1/*3 | *1/*1 | Metoprolol | ||
17 | 78 | NSIP, died from cardiac failure | *1/*6 | AS: 1.0 | (IM) | *1/*1 | *1A/*1B | *3/*3 | *2/*2 | Metoprolol | ||
18 | 90 | NSIP, died from cardiac failure | *1/*6 | AS: 1.0 | (IM) | *1/*2 | *1A/*1A | *3/*3 | *1/*1 | |||
19 | 77 | NSIP, died from lung carcinoma | *1/*4 | AS: 1.0 | (IM) | *1/*1 | *1A/*1A | *3/*3 | *1/*1 | |||
20 | 72 | NSIP, no follow-up data yet | *1/*4 | AS: 1.0 | (IM) | *1/*3 | *1A/*1A | *3/*3 | *1/*1 | Metoprolol | ||
21 | 79 | IPF, no follow-up data yet | *4/*4 | AS: 0.0 | (PM) | *1/*1 | *1A/*1A | *3/*3 | *1/*1 | |||
22 | 80 | IPF, no follow-up data yet | *1/*5 | AS: 1.0 | (IM) | *1/*1 | *1A/*1A | *3/*3 | *1/*1 |
CYP2D6 Phenotypes | Cases (n = 22) | Healthy Volunteers (n = 78) |
---|---|---|
Poor metabolizer | 9 (41%) | 8 (10.3%) |
Intermediate metabolizer | 13 (59%) | 19 (24.4%) |
Extensive metabolizer | 0 (0%) | 51 (65.3%) |
Ultra-rapid metabolizer | 0 (0%) | 0 (0%) |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Jessurun, N.T.; Wijnen, P.A.; Bast, A.; van Puijenbroek, E.P.; Bekers, O.; Drent, M. Tamsulosin Associated with Interstitial Lung Damage in CYP2D6 Variant Alleles Carriers. Int. J. Mol. Sci. 2020, 21, 2770. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21082770
Jessurun NT, Wijnen PA, Bast A, van Puijenbroek EP, Bekers O, Drent M. Tamsulosin Associated with Interstitial Lung Damage in CYP2D6 Variant Alleles Carriers. International Journal of Molecular Sciences. 2020; 21(8):2770. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21082770
Chicago/Turabian StyleJessurun, Naomi T., Petal A. Wijnen, Aalt Bast, Eugène P. van Puijenbroek, Otto Bekers, and Marjolein Drent. 2020. "Tamsulosin Associated with Interstitial Lung Damage in CYP2D6 Variant Alleles Carriers" International Journal of Molecular Sciences 21, no. 8: 2770. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21082770